⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
UPB News
Upstream Bio, Inc. Common Stock
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
globenewswire.com
UPB
Form 8-K
sec.gov
UPB
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
globenewswire.com
UPB
Form 8-K
sec.gov
UPB
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
globenewswire.com
UPB
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
globenewswire.com
UPB
Form 8-K
sec.gov
UPB
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
globenewswire.com
UPB
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
globenewswire.com
UPB
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
globenewswire.com
UPB